Mr. Doug Bost is a Co-Founder and CEO of JETA Molecular, as well as a Board Member and Vice-President of Transplant Monitoring at Omixon Biocomputing in Budapest, Hungary. JETA is diagnostics company focused on commercialization of non-invasive reagent and software solutions intended for monitoring recipients of allogeneic stem cell transplants. Prior to founding JETA, Mr. Bost was Director of Human Genetic and Transplantation Diagnostics R&D at Celera/Quest Diagnostics Mr. Bost received his B.A. in Microbiology and Immunology from the University of California, Berkeley, and is also the primary inventor of multiple issued patents related to kits and methods of selective nucleic acid isolation.